122 related articles for article (PubMed ID: 17058687)
21. 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Cannistra SA
Gynecol Oncol; 1993 Nov; 51(2):292-4. PubMed ID: 8276314
[No Abstract] [Full Text] [Related]
22. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Manyak MJ; Hinkle GH; Olsen JO; Chiaccherini RP; Partin AW; Piantadosi S; Burgers JK; Texter JH; Neal CE; Libertino JA; Wright GL; Maguire RT
Urology; 1999 Dec; 54(6):1058-63. PubMed ID: 10604708
[TBL] [Abstract][Full Text] [Related]
23. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
[TBL] [Abstract][Full Text] [Related]
24. Detection of recurrent colorectal carcinoma with In-111 CYT-103 scintigraphy in a patient with nondiagnostic MRI and CT.
Edlin JP; Kahn D
Clin Nucl Med; 1994 Nov; 19(11):1004-7. PubMed ID: 7842571
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
[TBL] [Abstract][Full Text] [Related]
26. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
Abdel-Nabi HH; Doerr RJ
Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
[TBL] [Abstract][Full Text] [Related]
27. Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
Silberstein EB; Saeks E
Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891
[TBL] [Abstract][Full Text] [Related]
28. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
Bohdiewicz PJ
J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
[TBL] [Abstract][Full Text] [Related]
29. Uptake of In-111 GYK-DTPA B72.3 monoclonal antibody in metastatic squamous cell carcinoma.
Blend MJ; De La Coates-Johnson R
Clin Nucl Med; 1994 Oct; 19(10):912-3. PubMed ID: 7805331
[No Abstract] [Full Text] [Related]
30. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
32. Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity.
Perkins AC; Vincent RM; Wastie ML; Denton GW; Amar S; Hardcastle JD
Nucl Med Commun; 1994 Dec; 15(12):981-90. PubMed ID: 7715898
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
Neal CE; Johnson DL; Cornwell VL; Markwell S
Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
[TBL] [Abstract][Full Text] [Related]
34. Appearance of a hepatic hemangioma on prostate immunoscintigraphy. Value of early images.
Krynyckyi BR; Ganeles A; Freeman LM; Zuckier LS
Clin Nucl Med; 1996 Jul; 21(7):541-3. PubMed ID: 8818467
[TBL] [Abstract][Full Text] [Related]
35. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
37. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response.
Winzelberg GG; Grossman SJ; Rizk S; Joyce JM; Hill JB; Atkinson DP; Sudina K; Anderson K; McElwain D; Jones AM
Cancer; 1992 Apr; 69(7):1656-63. PubMed ID: 1551051
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunolocalization of breast cancer using BrE-3 monoclonal antibody.
Kramer EL; DeNardo SJ; Liebes L; Noz ME; Kroger L; Glenn SD; Furmanski P; Ceriani R
Adv Exp Med Biol; 1994; 353():181-92. PubMed ID: 7985537
[No Abstract] [Full Text] [Related]
39. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H
AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050
[TBL] [Abstract][Full Text] [Related]
40. Imaging of bronchial carcinoid tumors associated to Cushing syndrome with 111In-Octreoscan scintigraphy and immunoscintigraphy with anti-chromogranin monoclonal antibodies. Report of two cases.
Carretta A; Chiesa G; Magnani P; Songini C; Melloni G; Zannini P; Grossi A
J Cardiovasc Surg (Torino); 1997 Apr; 38(2):191-4. PubMed ID: 9201136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
